Back to search
FDAFDA · Food and drugs·Recall number D-0096-2023

Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, Maryland 21801, NDC 59746-113-06

Published January 11, 2023 · Recall initiated: December 27, 2022

Summary

FDA records drug Class III recall D-0096-2023, published January 11, 2023 and initiated December 27, 2022. Recalling firm: Jubilant Cadista Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 14,061 bottles; Lot: Lot#: 21P0336, Exp: 04/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.

What to do

Voluntary: Firm initiated · Letter

Get an email if PROCHLORPERAZINE MALEATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PROCHLORPERAZINE MALEATE
Manufacturer
Jubilant Cadista Pharmaceuticals, Inc.
Distributor
Nationwide in the USA.
UPC
0359746113063
Lot
Lot#: 21P0336, Exp: 04/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, Maryland 21801, NDC 59746-113-06 recalled?

Yes. FDA published recall D-0096-2023 on January 11, 2023. Reported hazard: Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PROCHLORPERAZINE MALEATE. UPC: 0359746113063.